Skip to main content

IAVI 003

Phase:
I
Status:
Completed
Strategies:
Viral Vector - Pox
Candidates:
MVA.HIVA
Countries:
United Kingdom
Volunteers:
8
Partners:
John Warin Ward, The Churchill, Headington, Oxford, UK; Medical Research Council (MRC), Oxford, UK.

 

Study Summary:

This is an open-label study with an MVA vector-based HIV-1 clade A candidate vaccine, MVA.HIVA, in HIV-uninfected healthy male and female volunteers at low risk of HIV infection. On Day 0 and Day 21 study participants will receive a single intradermal injection of 5x10^7 pfu in 0.1ml in the latero-dorsal aspect over the deltoid muscle.